Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05806762 · ClinicalTrials.gov registry record
Prediction of Rehospitalization Following a Sepsis Admission Using a Wearable Biopatch
A clinical trial of Sepsis, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05806762: Recruiting study of Sepsis, sponsored by University of California, San Diego.
NCT05806762 is a study of Sepsis that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 200 participants, below the 6,562-participant average among 90 other Sepsis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05806762, a study of Sepsis, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn about the utility of biopatches predicting 30-day readmissions in patients discharged from the hospital with sepsis. The main question\[s\] it aims to answer are: • Does the application of a biopatch provide data that can improve prediction of an unplanned 30-day readmission following a hospitalization for sepsis. Participants will be asked to wear a biopatch on their chest for 30-days following hospital discharge or until readmission to the hospital.
Primary Outcome
Patients with an index hospitalization with sepsis will be followed to see if they have an unplanned readmission to the hospital.
Conditions Studied
Interventions
- DEVICE BioIntellisense
Study Locations (1)
California
- UC San Diego Health - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2027-05-02 |
What NCT05806762 shows while recruiting
NCT05806762 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 6,562-participant average among 90 other Sepsis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which BioIntellisense is the first listed.
NCT05806762 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05806762 about?
NCT05806762 is a clinical study titled "Prediction of Rehospitalization Following a Sepsis Admission Using a Wearable Biopatch". The goal of this observational study is to learn about the utility of biopatches predicting 30-day readmissions in patients discharged from the hospital with sepsis. The main question\[s\] it aims to answer are: • Does the application of a biopatch provide data that can improve prediction of an un...
What is the current status of trial NCT05806762?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-05-01. Estimated completion is 2027-05-02.
What conditions does trial NCT05806762 study?
This clinical trial studies the following conditions: Sepsis.
What interventions are being tested in trial NCT05806762?
The interventions under investigation include: BioIntellisense (DEVICE).
Who is sponsoring clinical trial NCT05806762?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05806762 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05806762's enrollment target sits among peer trials
200 42nd of 90 higher than 46 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI